KR101895969B1 - Anti-inflammatory composition comprising corn cob extract - Google Patents

Abstract

The present invention relates to an anti-inflammation composition comprising a corn cob extract, and more particularly, the present invention relates to a composition for preventing or treating inflammatory gastrointestinal diseases comprising a corn cob extract. The corn cob extract of the present invention has no side effects in the human body and has an excellent therapeutic effect on inflammatory gastrointestinal diseases such as gastritis and colitis, and thus can be usefully used as medicines and health functional foods.

Description

The present invention relates to an anti-inflammatory composition comprising corn cob extract,

The present invention relates to a composition for preventing or treating inflammatory gastrointestinal diseases, including corncobs extract, and more particularly to a composition for anti-inflammation comprising corncob activity.

Inflammation reaction refers to the mechanism of restoration and regeneration of an injured area when an invasion of any physical change such as physical action, chemical substance, bacterial infection, etc. is applied to a living body or tissue.

Colitis is an inflammation of the large intestine caused by a variety of causes, including tenesmus, abdominal bloating, lower abdomen, and diarrhea. The main symptoms are mucus, pus or blood There is also a case of mixing. Colitis may be classified into infectious colitis and non - infectious colitis depending on the cause and may be classified into acute colitis and chronic colitis according to the onset period. Acute colitis may be caused by amebic dysentery, bacterial dysentery, salmonella, or pseudomembranous enteritis caused by antibiotics. Chronic colitis may be caused by ulcerative colitis, Crohn's disease, tuberculosis, syphilis, or X-rays. In addition, colitis includes not only inflammatory bowel disease (IBD) but also irritable bowel syndrome (IBS). The causes of ulcerative colitis (UC) and Crohn's disease (CD), the most common inflammatory bowel disease (IBD), have yet to be clearly identified, and severe chronic diarrhea and hemolytic It can cause diarrhea, and it is difficult to cure, and it has the characteristic of repeated improvement and deterioration. Ulcerative colitis is a disease in which erosions (erosions) and ulcers are continuously formed in the mucous membranes of the large intestine. Bleeding, dyspepsia, diarrhea and abdominal pain occur in the colon. In severe cases, systemic symptoms such as fever, weight loss and anemia appear . Ulcerative colitis may also occur anywhere in the gastrointestinal tract. Crohn's disease is a disease in which ulcer and other lesions occur in a random part of the digestive tract from the mouth to the anus. In addition to abdominal pain, diarrhea and stool, severe cases include fever, hemorrhage, weight loss, And the like. Ulcerative colitis and Crohn 's disease are different in terms of lesions and inflammatory symptoms, but they are similar in many respects.

In the past, the incidence of ulcerative colitis and Crohn's disease was known to be high in Westerners, but in recent years, the number of patients has also increased in Korea and other countries due to changes in lifestyle such as eating habits. However, there is a reason why the cause is unclear, and fundamental treatment is not established. For this reason, it is not aimed at complete treatment, but medicines which alleviate symptoms and maintain such state as long as possible are used. Aminosalicylic acid preparations, adrenocorticosteroids, immunosuppressants and the like are mainly used as medicines for such symptomatic therapy, but various side effects have been reported. For example, salazosulfapyridine, which is frequently used as an aminosalicylic acid preparation, has been reported to have side effects such as nausea, vomiting, anorexia, rash, headache, liver damage, leukocytosis, abnormal red blood cells, proteinuria and diarrhea. Adrenocortical steroids are generally used for oral administration of prednisolone, enema, suppository, intravenous injection, etc. However, side effects such as gastric ulcer necrosis caused by gastric ulcer or long-term use are strong. However, since discontinuation of the medication recurs, the medicines must be continuously used.

On the other hand, the stomach stores the food that comes in through the esophagus, breaks it down easily, and controls the sending of the food to the duodenum, so that the pancreas enzyme is secreted and harmonized to efficiently digest and absorb. The stomach secretes stomach acid, which is strong acid to digest it when food comes in. At this time, the gastric mucosal protective layer acts to prevent the stomach acid from damaging the gastric mucosa. The gastric mucosal protective layer that protects the stomach is susceptible to attack from various kinds of factors. Typical attack factors include non-steroidal anti-inflammatory drugs (NSAIDs) such as gastric acid, alcohol, and aspirin, bacteria such as Helicobacter pylori, stress-induced microcirculatory disorders of gastric mucosa and hypotension. These factors cause erosion with erosion, redness, hemorrhage and edema when the gastric mucosal layer is damaged, and gastric ulcers occur when the damage is severe and the gastric mucosa penetrates to the lower mucosa and muscle layer. In addition, duodenal ulcer occurs when the duodenal mucosa is damaged due to the above factors, and the lesion progresses more than the mucosal layer on the surface most than the mucosal layer. Therefore, in order to treat gastrointestinal diseases such as gastritis, gastric ulcer, and duodenal ulcer induced by the above-described attack factors, it is desirable to inhibit gastric acid secretion, inhibit proliferation of Helicobacter pylori, promote mucous secretion, promote epithelial cell regeneration, Drugs with efficacy are needed.

Currently, the most typical treatment for gastrointestinal diseases is antacid which neutralizes excessive secretion liquid, histamine H2 receptor antagonist which suppresses gastric acid secretion, proton pump inhibitor, Prostaglandin, or gastric mucosal protective agent, which can inhibit the gastric mucosa.

Antacids among the above drugs are for temporary short-acting, not fundamental treatment, and exhibit drug efficacy by lowering the activity of pepsin by raising the pH in the stomach. However, when using antacids, side effects such as constipation, diarrhea, metabolic alkalosis and urinary nodule have been reported by the administration of inorganic substances. In recent years, acid rebound due to antacids has become a problem.

Due to such limitations, there is a demand for the development of a therapeutic agent for inflammatory gastrointestinal diseases which is excellent in efficacy, safe, and does not cause side effects.

Accordingly, the present inventors have conducted studies to produce natural extracts having excellent therapeutic activity, and as a result, they have found that corncobs extract has no harmful effects on the human body and has a therapeutic effect on inflammatory gastrointestinal diseases such as gastritis and colitis, Completed.

Korean Patent Publication No. 10-2016-0036202 (April 26, 2014)

 Lee, JY, et al. "Quality Characteristics of Purple Corn Seed Extracts by Extraction Time." Journal of Applied Biological Chemistry 58.4 (2015): 339-344.  Wei, Dongwei, et al. "β-Sitosterol solubility in selected organic solvents." Journal of Chemical & Engineering Data 55.8 (2010): 2917-2919.

It is an object of the present invention to provide a composition for the prophylaxis or treatment of inflammatory gastrointestinal diseases, including corncobs extract.

In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing or treating an inflammatory gastrointestinal tract disease comprising corncob meal extract.

The present invention provides a food composition for preventing or ameliorating an inflammatory gastrointestinal tract disease comprising corncob meal extract.

The corncob meal extract of the present invention has no side effects in the human body and has an excellent therapeutic effect on inflammatory gastrointestinal diseases such as gastritis and colitis, and thus can be usefully used as medicines and health functional foods.

FIG. 1 is a graph showing the effect of corncobs extract on the expression of inflammatory factors in AGS (rat gastrointestinal mucosa cells). FIG.
FIG. 2 is a graph showing the change in the size of inflammation sites caused by administration of corncob meal extract in an animal model of gastritis. FIG.
FIG. 3 is a graph showing the results of H & E staining (A) and tissue inflammation analysis (B) of stomach tissue after administration of corn borer extract to a gastritis animal model.
FIG. 4 is a graph showing the results of immunohistochemical staining of the gastric tissue after the ingestion of corncob meal extract into a gastric animal model (A: i-NOS, B: TNF-a).
FIG. 5 is a graph showing the change in body weight (A) and DAI (B) by administration of corn borer extract in an animal model of colitis.
FIG. 6 is a diagram showing the results of checking the change in colon length by administration of corncob meal extract in an animal model of colitis. FIG.
FIG. 7 is a diagram showing the results of H & E staining (A) and tissue inflammation analysis (B) of colonic tissues after administration of corn borer extract to an animal model of colitis.
FIG. 8 is a graph showing the result of administration of a corn borer extract to an animal model of colitis, followed by isolation of a colon tissue fragment and tissue immunostaining (A: i-NOS, B: TNF-a).

The present invention provides a composition for preventing or treating an inflammatory gastrointestinal tract disease comprising corncob meal extract.

The composition comprises a pharmaceutical composition and a food composition.

Hereinafter, the present invention will be described in more detail.

In the present invention, a 'corn cob' is a soft tissue that is visible at the center surrounded by a vascular bundle arranged in a tubular form at the stem of a plant. The cornstarch comprises 6.7 to 14.9% moisture, 4.3 to 12.9% crude protein, 0.5 to 1.4% crude fat, 4.9 to 13.0% of ash and 27 to 54% of dietary fiber, . The corn borer which is the active ingredient of the present invention has a high added value because it is a generally used by-product.

In the present invention, the term "extract" means an extract obtained by extracting the cornstarch, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a controlled preparation or a purified product of the extracted solution, Extracts themselves and extracts of all formulations which can be formed using extracts.

Examples of the solvent that can be used to obtain the extract include water, alcohols having 1 to 4 carbon atoms, a mixed solvent thereof, and the like, but are not limited thereto.

Examples of the method for extracting the above extract include hot water extraction, cold extraction, reflux cooling, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression. The extract may further be subjected to a conventional fractionation process, and may be purified using a conventional purification method.

In the present invention, 'inflammatory gastrointestinal disease' refers to inflammatory diseases caused by various causes in the gastrointestinal tract such as stomach, small intestine, and large intestine. Inflammatory bowel disease (specifically, ulcerative colitis, Crohn's disease), irritable bowel syndrome (in particular, hyaline type irritable bowel syndrome), inflammatory bowel disease, , Or gastritis. ≪ / RTI >

The large intestine includes the rectum, the S-phase, the descending colon, the transverse colon, or the ascending colon. In the case of colitis, inflammation occurs in at least one site of the site, And the like.

The corncob meal extract of the present invention has no side effects in the human body and has an excellent therapeutic effect on inflammatory gastrointestinal diseases such as gastritis and colitis, and thus can be usefully used as medicines and health functional foods.

In one aspect, the invention provides a pharmaceutical composition for the prophylaxis or treatment of inflammatory gastrointestinal diseases, including corncobs extract.

The pharmaceutical composition according to the present invention is prepared for the purpose of prevention or treatment of diseases, and can be formulated into various forms according to ordinary methods. When the composition of the present invention is formulated into a pharmaceutical composition for the purpose of preventing or treating inflammatory gastrointestinal diseases, it may further comprise suitable carriers, excipients and diluents conventionally used in the production of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose , Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The term "administering" as used herein means providing the subject invention with a composition of the invention in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. The composition may be administered once a day, or divided into several doses. The dosage of the pharmaceutical composition of the present invention may be, for example, 1 mg / kg to 1,000 mg / kg per day, preferably 10 mg / kg to 500 mg / kg per day, And are not intended to limit the scope of the invention.

The route of administration and the mode of administration of the pharmaceutical composition of the present invention may be independent of each other, and the method is not particularly limited, and any route of administration and administration method may be used as long as the pharmaceutical composition can reach the desired site . The pharmaceutical composition may be administered orally or parenterally, for example, orally, rectally, intravenously, intramuscularly or subcutaneously, preferably orally.

The pharmaceutical composition of the present invention may contain one or more known active ingredients having an effect of preventing or treating an inflammatory gastrointestinal tract disease together with a corn borer extract.

The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention and treatment of inflammatory gastrointestinal diseases.

In another aspect, the present invention provides a food composition for preventing or ameliorating an inflammatory gastrointestinal disorder, comprising corncob meal extract.

In the present invention, the food composition may be prepared by a method commonly used in the art, and may be prepared by adding raw materials and ingredients that are conventionally added in the art. The formulations of the food composition may also be prepared without limitation as long as they are formulations acceptable as food compositions.

The food composition according to the invention may, for example, be in the form of a health functional food.

In the present invention, the term " health functional food " refers to a food group imparted with added value to function or express the function of the food by physical, biochemical, biotechnological techniques or the like, Means a food which has been designed and manufactured so that the body's control function regarding disease prevention and recovery is sufficiently expressed to the living body. For the purpose of the present invention, the health functional food is intended to prevent or ameliorate inflammatory gastrointestinal diseases, for example, a health functional food for preventing and improving gastritis or colitis.

Foods according to the present invention include, for example, various foods, beverages, gums, tea, vitamin complexes, and functional foods. Foods also include special nutritional foods (eg crude oil, spirits, baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramie noodles, (For example, soy sauce), candy, chocolate, gum, ice cream, milk products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods (Eg, fruit juices, etc.), beverages (eg fruit drinks, vegetable beverages, beverages, fermented beverages, etc.), natural seasonings (eg, ramen soup, etc.), food additives. The food, beverage or food additive may be prepared by a conventional production method.

When the composition of the present invention is used as a health functional food additive, the composition may be added as it is or may be used together with other health functional food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use. In general, the composition of the present invention may be added in an amount of preferably 50 parts by weight or less, more preferably 25 parts by weight or less, with respect to the raw material in the production of food or beverage. However, in the case of long-term intake intended for health control and hygiene, the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount in the above range.

The food composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient as well as conventional food compositions in addition to the corncob activity extract which is an effective ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. The above-described flavors can be advantageously used as natural flavorings (tau martin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.).

In addition to the corncob meal extract, the food composition may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the food composition of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks.

Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples. The following Examples and Experimental Examples are provided only for illustrating the present invention, but the present invention is not limited by the following Examples and Experimental Examples.

Example  1. Corn An innocent  Preparation of extract

Corn corps was isolated from corn. 50 g of dried cornstarch were placed in a 1 L bottle and 500 mL dH ₂ O, 10 times the amount of corn inoculated, was added and mixed. After that, the mixture was subjected to hydrothermal extraction for 15 minutes under high temperature and high pressure conditions of 110 ° C and 0.4 kgf / cm ³ (5.69 PSI), followed by filtration with a 0.2 μm syringe filter. The Zm extract obtained through the above procedure was used in the following experiments.

Example  2. Corn An innocent  Analysis of components of extract

2-1. corn An innocent  Freeze-drying and dry weight analysis of extract

1 ml of the corncob meal extract obtained in Example 1 was placed in a 1.5 ml tube and lyophilized for 24 hours using a freeze dryer (Martin Christ, Alpha 1-4 LDplus, Osterode am Harz, Germany) , 0.021 mbar). Then, the dry weight of the sample was measured, and the average value of the dry weights of the three sets (A, B, C) was calculated. The results are shown in Table 1.

A B C Average
(A, B, C) Dry powder
(mg / ml) 4 3 3 3.33 ± 0.58

2-2. corn An innocent  Analysis of Polyphenol Contents in Extracts

First, 0.17012 g of gallic acid (SIGMA, G7384-100G, USA) was dissolved in methanol (ARMRESCO, K977-1L, USA) to a final volume of 1 ml to prepare 1M gallic acid. (1uM, 5uM, 10uM, 25uM, 75uM, 0.3mM, 0.7mM, 2mM, 6mM) were diluted in methanol and used as a standard solution for polyphenol content analysis.

Next, 80 μl of 2N Folin and Ciocalteu's phenol reagent (SIGMA, F9252-1L, USA) was diluted in 99.98 ml of dH ₂ O to prepare a 10% solution of Folin and Ciocalteu's phenol reagent (Solution A). On the other hand, 0.74 g of sodium carbonate (SIGMA, 223484-500G, USA) was dissolved in dH ₂ O to prepare a 700 mM sodium carbonate reaction solution (Solution B). The standard solution or the cornstarch extract was added to a 1.5 ml tube in an amount of 100 μl each, followed by mixing with 200 μl of Solution A and reacting at room temperature for 1 minute. 800 Solution of Solution B was added to the mixed solution, and the mixture was reacted at 37 캜 for 30 minutes. After the reaction was completed, the reaction was stopped by adding ice to 1 ml of cuvette (HellmaAnalytics, 104-10-46, Germany) and absorbance was measured at 765 nm using a spectrophotometer (Optizen, Optizen POP Bio, Korea). The results are shown in Table 2.

A B C Average
(A, B, C) Total polyphenol (mg / ml) 0.311 0.314 0.314 0.313 ± 0.002

2-3. corn An innocent  Analysis of catechin content in extracts

First, 1 mg of catechin was dissolved in 1 ml of methanol, and the mixture was divided into 0, 1, 5, 10, and 20 ul in a 1.5 ml tube. Methanol was added to each tube in an amount of 20, 19, 15, It was used as a standard solution for catechin content analysis of whole polyphenols.

Next, 0.1 g of vanillin (JUNSEI, Japan) was dissolved in 10 ml of methanol (ARMRESCO, USA) to prepare a 1% vanillin solution (solution A). Meanwhile, 8% HCl (Daejung, Korea) diluted in methanol and solution A were mixed at a volume ratio of 1: 1 to prepare a reaction solution (solution B). The reaction solution (Solution B) was maintained at 30 ° C for 15 minutes, 20 μl of the standard and 20 μl of the cornstarch extract were pre-incubated at 30 ° C for 5 minutes. Then, 100 μl of the reaction solution (Solution B) 20ul of standard solution or corncob meal extract was mixed and reacted at 30 ° C for 20 minutes, and the reaction was stopped by adding ice. Then, 110 ul of each solution was added to a 96-well plate (SPL Life Sciences, Korea), and the absorbance was measured at 492 nm using a microplate reader (Sunrise ^™ , Tecan, Switzerland). The results are shown in Table 3.

A B C Average
(A, B, C) Catechin
(ug / ml) 0.059 0.058 0.063 0.060 0.003

Experimental Example  1. Anti-inflammatory activity assay in gastric mucosa cells

AGS (ATCC® CRL-1739 ™), a gastric mucosal cell of the rat, was used to confirm the anti-inflammatory activity of the corncobs extract in vitro. More specifically, AGS cells were suspended in RPMI 1640 1X (RPMI 1640; CORNING, USA) containing L-glutamine, 10% FBS (Fetal Bovine Serum; GemCell, California, USA), 1% penicillin / streptomycin (Thermo Fisher Scientific, , Utah, USA) and maintained in an incubator (Thermo scientific, Massachusetts, USA) at 36.5 ° C and 5% CO ₂ . 5x10 ⁵ of the AGS cells were seeded on a 100 mm plate and cultured for 12 hours. Each well was treated with vehicle or cornstarch extract (10 ^-2 , 10 ^-3 , 10 ^-4 dilution) and allowed to react for another 12 hours. After the cells were collected, the cells were treated with RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40) and 1% PMSF for 30 minutes, Proteins were isolated. Western blotting was performed according to methods known in the art using the protein. The primary antibodies were COX2 (Santa Cruz Biotechnology, California, USA) and IL-6 (Santa Cruz Biotechnology, California, USA) as the primary antibodies. The results are shown in Fig.

As shown in FIG. 1, it was confirmed that anti-inflammatory effects such as COX2 and IL-6 expression, which are inflammation markers, in the gastric mucosal cells were statistically decreased by the treatment of corncob meal extract.

Experimental Example  2. Anti-inflammatory activity test in gastric animal model

A gastritis model was prepared by administering 80 mg / kg of indomethacin to 6-week-old male rats via oral route and continuing for 6 hours (G2). To the above gastrointestinal animal model, the corncob meal extract (10-fold dilution [G4], 100-fold dilution [G5]) of the extract obtained in Example 1 was respectively administered to confirm the therapeutic effect. G1 is a normal group of rats that does nothing, and G3 is a group administered with lansoprazole, a gastritis treatment. After the end of the experiment, each rat was autopsied and gastric inflammation site was measured. The gastric tissues were separated, and the inflammation level was calculated by H & E staining and tissue observation. In addition, immunohistochemistry for i-NOS and TNF-a was performed using gastric tissue sections. The results of the above experiments are shown in FIG. 2 to FIG.

As shown in Fig. 2, it was confirmed that the degree of gastric inflammation by indomethacin was statistically significant (P > 0.05) by administration of corncob meal extract.

In addition, as shown in FIG. 3, the results of H & E staining and tissue observation (inflammation, ulceration, hyperplasia) showed that inflammation levels were remarkably improved by administration of corn borer extract.

In addition, as shown in Fig. 4, the expression of i-NOS (A) and TNF-a (B), which are typical inflammation markers, was remarkably decreased by administration of corncob activity.

Thus, it was confirmed that the corncob meal extract according to the present invention has an excellent therapeutic effect in a gastritis animal model.

Experimental Example  3. Anti-inflammatory activity assay in colitis animal model

5-week-old male mice were fed with 2% DSS (dextran sulfate sodium) for 1 week at free-feeding to induce colitis. The prevention group means a group of oral administration of corncobs extract (10 times diluted [G3], 100 times diluted [G5])] once a day / day from 1 week before administration of DSS, group) refers to a group obtained by oral administration of corncob meal extract (10-fold diluted [G4], 100-fold diluted [G6])] at a time / day at the same time as DSS administration. G1 is a normal mouse to which nothing is administered, and G2 is a disease-induced group administered only DSS. After the completion of the experiment, each mouse was sacrificed and the body weight was measured, and the DAI (Disease activity index) was analyzed. At this time, DAI was measured by the following three items: [Body weight loss]: none = 0; 1-5% = 1; 5-10% = 2; 10-15% = 3; above 15% = 4, [Stool consistency]: normal = 0; soft = 2; diarrhea = 4, [Presence of blood in stool]: none = 0; slight bleeding = 2; massive bleeding = 4. In addition, colon length of each mouse was measured, colon tissue was separated, and the inflammation level was calculated by H & E staining and tissue observation. In addition, immunohistochemistry for i-NOS and TNF-a was performed using a colon tissue fragment. The results of the above experiments are shown in Figs.

As shown in FIG. 5, it was confirmed that the rapid weight loss caused by the incidence of colitis was alleviated by the administration of the corn borer extract (A), and the DAI of the corn borer extract-administered group was significantly lower than that of the disease-induced group (B).

In addition, as shown in FIG. 6, colon length was significantly reduced by the onset of colitis in the disease-induced group, but it was confirmed that there was no significant difference between the group treated with corn onion extract and the normal group.

7, as a result of H & E staining and tissue observation (inflammation, ulceration, hyperplasia), it was confirmed that the inflammation level was remarkably improved by the administration of corncob meal extract. As shown in FIG. 8, The expression of i-NOS (A) and TNF-a (B) was remarkably decreased by the administration of corn borer extract.

Thus, it was confirmed that the corncobs extract according to the present invention has excellent preventive and therapeutic effects in an animal model of colitis.

From the above results, it was confirmed that corncobs extract had a remarkably excellent anti-inflammatory effect in an animal model of inflammatory gastrointestinal tract diseases including gastritis and colitis.

Hereinafter, the pharmaceutical composition of the present invention and the preparation example of the food composition will be described, but the present invention is not intended to be limited but is specifically described.

Formulation example  1. Preparation of pharmaceutical compositions

1-1. Sanje  Produce

Corn onion extract 2 g

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

1-2. Manufacture of tablets

Corn onion extract 100 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

1-3. Preparation of capsules

Corn onion extract 100 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

Formulation example  2. Preparation of food composition

2-1. Manufacture of Health Functional Foods

Corn onion extract 100 mg

Vitamin mixture quantity

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Claims (6)

A pharmaceutical composition for the prophylaxis or treatment of inflammatory gastrointestinal diseases, comprising corncobacca high-pressure hot-water extract containing polyphenols and catechins.
The pharmaceutical composition for preventing or treating inflammatory gastrointestinal diseases according to claim 1, wherein the corncob meal extract contains polyphenols in a concentration of 0.311 to 0.314 mg / ml.
The pharmaceutical composition for preventing or treating inflammatory gastrointestinal diseases according to claim 1, wherein the corncoble high-pressure hot-water extract contains catechin at a concentration of 0.059 to 0.063 μg / ml.
The pharmaceutical composition according to claim 1, wherein the inflammatory gastrointestinal disorder is at least one selected from the group consisting of gastritis, ulcerative colitis, Crohn's disease and irritable bowel syndrome.
A food composition for preventing or ameliorating an inflammatory gastrointestinal tract disease comprising corncobacca high-pressure hot-water extract containing polyphenols and catechins.
The food composition according to claim 5, wherein the inflammatory gastrointestinal disorder is at least one selected from the group consisting of gastritis, ulcerative colitis, Crohn's disease and irritable bowel syndrome.

Images